Jin Huang

5PUBLICATIONS
0CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Dec 05, 2021
First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis.

Youwen Zhu, Huabin Hu, Dong Ding

|Feb 11, 2021
Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.

Shuosha Li, Huabin Hu, Dong Ding

|Sep 12, 2020
Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.

Dong Ding, Huabin Hu, Yin Shi

|Mar 21, 2020
Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.

Dong Ding, Huabin Hu, Mengting Liao

|Feb 29, 2020
Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.

Jiaqi Han, Desheng Xiao, Chongqing Tan

Pageof 1

Frequent Collaborators